How we manage Philadelphia‐negative myeloproliferative neoplasms in pregnancy

SE Robinson, CN Harrison - British journal of haematology, 2020 - Wiley Online Library
The combined incidence of classical Philadelphia‐negative myeloproliferative neoplasm
(MPN) is 6–9/100 000 with a peak frequency between 50 and 70 years. MPN is less frequent …

[HTML][HTML] The evolving pharmacotherapeutic landscape for the treatment of sickle cell disease

SK Ballas - Mediterranean Journal of Hematology and Infectious …, 2020 - ncbi.nlm.nih.gov
Sickle cell disease (SCD) is an extremely heterogeneous disease that has been associated
with global morbidity and early mortality. More effective and inexpensive therapies are …

Society for Maternal-Fetal Medicine Consult Series# 68: Sickle cell disease in pregnancy

RG Sinkey, FJ Ogunsile, J Kanter, C Bean… - American journal of …, 2024 - Elsevier
Pregnant individuals with sickle cell disease have an increased risk of maternal and
perinatal morbidity and mortality. However, prepregnancy counseling and multidisciplinary …

Evidence-based obstetric management of women with sickle cell disease in low-income countries

BB Afolabi, OA Babah, TA Adeyemo - Hematology, 2022 - ashpublications.org
Pregnancy in women with sickle cell disease (SCD) is fraught with complications, some of
which are life-threatening. Managing pregnancy in these women can be challenging …

Tolerability and age‐dependent toxicokinetics following perinatal hydroxyurea treatment in Sprague Dawley rats

MC Huang, KJ Turner, M Vallant… - Journal of Applied …, 2021 - Wiley Online Library
Hydroxyurea (HU) is a valuable therapy for individuals with sickle cell anemia. With
increased use of HU in children and throughout their lives, it is important to understand the …